Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ultra fast-acting insulin analogue - Adocia

Drug Profile

Ultra fast-acting insulin analogue - Adocia

Alternative Names: BC 106 Insulin Lispro; BC 222 Insulin Lispro; BC Lispro; BioChaperone Lispro; BioChaperone® insulin analogue; BioChaperone® insulin lispro; BioChaperone® Lispro U100; BioChaperone® Lispro U200; BioChaperone® Ultra Fast Lispro; THDB-0206

Latest Information Update: 25 Sep 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Adocia
  • Developer Adocia; Tonghua Dongbao Pharmaceutical
  • Class Antihyperglycaemics; Insulins; Pancreatic hormones; Recombinant proteins
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Tyrosine aminotransferase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Type 2 diabetes mellitus
  • Phase II/III Type 1 diabetes mellitus

Most Recent Events

  • 22 Sep 2023 Meitheal Pharmaceuticals enters into an exclusive licensing agreement with Tonghua Dongbao Pharmaceutical to commercialize products in the US
  • 06 May 2022 Phase-III trial for Type 2 diabetes mellitus in China (SC) (NCT05834868)
  • 15 Oct 2021 Adocia and Tonghua Dongbao Pharmaceutical plans a phase III trial for Type-1 diabetes mellitus in the USA and Europe in 2022
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top